Accès ouvert · CC BY

Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV

Article scientifique 2025 Sciences de la santé Anglais

Résumé

Dolutegravir resistance is predominantly reported in antiretroviral therapy-experienced individuals. We describe an infant who developed high-level resistance to abacavir, lamivudine, and dolutegravir within 97 days of initiation, despite initial wild-type infection. Causative factors likely include probable sub-therapeutic antiretroviral drug levels, poor tolerance, severe immunocompromise, and a high pre-treatment viral load. What this study adds: The evolution of DTG resistance from a confirmed transmitted wild-type virus in this infant is more rapid than previously described. Identification of risk factors for developing DTG resistance in infants requires further investigation.

Citer ce document

O’Connell, N., Mollendorff, T.-L. V., Zyl, G. U. V., Korsman, S. N., & Nuttall, J. (2025). Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV. Southern African Journal of HIV Medicine. https://doi.org/10.4102/sajhivmed.v26i1.1750

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 29/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 14

Téléchargements (hors robots) : 0

Méthode de comptage